» Articles » PMID: 37798649

RAD51 is a Poor Prognostic Marker and a Potential Therapeutic Target for Oral Squamous Cell Carcinoma

Overview
Journal Cancer Cell Int
Publisher Biomed Central
Date 2023 Oct 5
PMID 37798649
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: RAD51 overexpression has been reported to serve as a marker of poor prognosis in several cancer types. This study aimed to survey the role of RAD51 in oral squamous cell carcinoma and whether RAD51 could be a potential therapeutic target.

Materials And Methods: RAD51 protein expression, assessed by immunohistochemical staining, was used to examine associations with survival and clinicopathological profiles of patients with oral squamous cell carcinoma. Lentiviral infection was used to knock down or overexpress RAD51. The influence of RAD51 on the biological profile of oral cancer cells was evaluated. Cell viability and apoptosis after treatment with chemotherapeutic agents and irradiation were analyzed. Co-treatment with chemotherapeutic agents and B02, a RAD51 inhibitor, was used to examine additional cytotoxic effects.

Results: Oral squamous cell carcinoma patients with higher RAD51 expression exhibited worse survival, especially those treated with adjuvant chemotherapy and radiotherapy. RAD51 overexpression promotes resistance to chemotherapy and radiotherapy in oral cancer cells in vitro. Higher tumorsphere formation ability was observed in RAD51 overexpressing oral cancer cells. However, the expression of oral cancer stem cell markers did not change in immunoblotting analysis. Co-treatment with RAD51 inhibitor B02 and cisplatin, compared with cisplatin alone, significantly enhanced cytotoxicity in oral cancer cells.

Conclusion: RAD51 is a poor prognostic marker for oral squamous cell carcinoma. High RAD51 protein expression associates with resistance to chemotherapy and radiotherapy. Addition of B02 significantly increased the cytotoxicity of cisplatin. These findings suggest that RAD51 protein may function as a treatment target for oral cancer.

Trial Registration: Number: KMUHIRB-E(I)-20190009 Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, approved on 20190130, Retrospective registration.

Citing Articles

Photonic Crystal Surface Mode Real-Time Imaging of RAD51 DNA Repair Protein Interaction with the ssDNA Substrate.

Nifontova G, Charlier C, Ayadi N, Fleury F, Karaulov A, Sukhanova A Biosensors (Basel). 2024; 14(1).

PMID: 38248420 PMC: 10813746. DOI: 10.3390/bios14010043.

References
1.
Wu R, Patel A, Tokumaru Y, Asaoka M, Oshi M, Yan L . High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. Breast Cancer Res Treat. 2022; 193(1):49-63. PMC: 8995390. DOI: 10.1007/s10549-022-06552-0. View

2.
Richardson C . RAD51, genomic stability, and tumorigenesis. Cancer Lett. 2005; 218(2):127-39. DOI: 10.1016/j.canlet.2004.08.009. View

3.
Li Y, Yu H, Luo R, Zhang Y, Zhang M, Wang X . Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma. J Surg Oncol. 2011; 104(6):617-22. DOI: 10.1002/jso.22018. View

4.
Chiu W, Fang P, Lee Y, Wang Y, Su Y, Hu S . DNA Repair Protein Rad51 Induces Tumor Growth and Metastasis in Esophageal Squamous Cell Carcinoma via a p38/Akt-Dependent Pathway. Ann Surg Oncol. 2019; 27(6):2090-2101. DOI: 10.1245/s10434-019-08043-x. View

5.
Chen Q, Cai D, Li M, Wu X . The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma. Oncol Rep. 2017; 38(2):767-774. PMC: 5561999. DOI: 10.3892/or.2017.5724. View